logo
Share SHARE
FONT-SIZE Plus   Neg

BioSante Pharma Reveals Positive Results Of Its Prostate Cancer Vaccine Study

Specialty pharmaceutical company BioSante Pharmaceuticals Inc (BPAX: Quote) Monday announced that the latest issue of The Lancet Oncology published the results from a Phase I dose escalation clinical study of GVAX Prostate cancer vaccine.

The results revealed that the GVAX Prostate cancer vaccine, used in treating metastatic castration-resistant prostate cancer patients in combination with ipilimumab, resulted in 53 percent of patients achieving at least stable disease, with two patients showing clear regression of metastases.

The results further revealed that 23 percent of patients in the higher dose cohorts had confirmed partial PSA response of greater than 50 percent from baseline.

The study further concluded that there were no serious adverse events in the lower dose Ipi cohorts and administration of immunotherapy was well tolerated and safe.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The Federal Communications Commission on Thursday voted along expected lines to adopt new rules to monitor Internet service providers to protect open access and innovation, pacifying consumers and tech companies like Netflix, while creating heartburn for cable and telecom companies. Google Inc. (GOOG, GOOGL) has made a $300 million investment in a fund that will finance residential power projects. SolarCity Corp. (SCTY) Thursday said it has created a fund expected to finance $750 million in residential solar projects with Google investing about $300 million. The new fund... As consumers' choice for mobile payment surges, with smartphone makers, Internet companies and credit card firms in the fray, no clear winner is yet to emerge in this financial landscape that is set to flourish and chisel the fate of businesses, shows a survey commissioned by Placecast.
comments powered by Disqus
RELATED NEWS
Trade BPAX now with 
Follow RTT